AbbVie (ABBV) Equity Ratio (2012 - 2026)

AbbVie has disclosed Equity Ratio across 15 years of filings, most recently posting 0.05 for Q1 2026.

• In Q1 2026, Equity Ratio fell 554.27% year-over-year to 0.05; the TTM figure through Mar 2026 stood at 0.05 (down 554.27% YoY), while the FY2025 annual figure was 0.02, down 198.08% from the prior year.
• Equity Ratio declined to 0.05 in Q1 2026, from 0.02 in the prior quarter.
• Over the last five years, Equity Ratio for ABBV reached as high as 0.12 in Q4 2022 and fell as low as 0.05 in Q1 2026.
• The 5-year median for Equity Ratio is 0.05 (2024), against an average of 0.05.
• Annual changes were most pronounced in 2022 — Equity Ratio gained 24.84% — and 2026, when it sank 554.27%.
• A 5-year view of Equity Ratio shows it stood at 0.12 in 2022, then sank by 38.03% to 0.08 in 2023, then sank by 67.75% to 0.02 in 2024, then plunged by 198.08% to 0.02 in 2025, then plunged by 99.81% to 0.05 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.05, 0.02, and 0.02 for Q1 2026, Q4 2025, and Q3 2025 respectively.